(Albany, USA) DelveInsight’s ‘Neuroendocrine Tumors Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Neuroendocrine Tumors therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Neuroendocrine Tumors pipeline domain.
For Neuroendocrine Tumors emerging drugs, the Neuroendocrine Tumors pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
To know more about the Neuroendocrine Tumors report offerings, click here @ Neuroendocrine Tumors Pipeline Insight
Key Takeaways from the Neuroendocrine Tumors Pipeline Report
- DelveInsight’s Neuroendocrine Tumors Pipeline analysis depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Neuroendocrine Tumors treatment.
- The leading Neuroendocrine Tumors companies include iangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Pfizer, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others are evaluating their lead assets to improve the Neuroendocrine Tumors treatment landscape.
- Key Neuroendocrine Tumors pipeline therapies in various stages of development include 177Lu-edotreotide PRRT, Axitinib, AlphaMedix, 64Cu MeCOSar Octreotate, Foslinanib, Belzutifan, Actinium-225 Dotate, Pelcitoclax, Debio 4126 controlled release, BI 764532, RO7616789, Satoreotide trizoxetan, rSIFN-co, CAM-2029, RRx-001, Lenvatinib, PEN-221, Belzutifan, Tirapazamine, Sunitinib, NP-101, PT217, FF-10850, Lurbinectedin, 23ME-00610, BLU-667, CC-223, Paltusotine, TAK 580, PV-10, NV 103, and others.
- In March 2023, RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, announced the completion of enrollment in the Phase 1b portion of the ACTION-1 Phase 1b/3 trial of RYZ101 in patients with SSTR+ gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who have progressed on Lutetium-177 labeled somatostatin analog therapy.
- In March 2023, NUCLIDIUM announced that the Neuroendocrine Tumors Research Foundation (“NETRF”) has selected the company and its collaboration partner the University Hospital Basel (Universitätsspital Basel, “USB”) as recipients of its Investigator Award. The grant will support the initiation and execution of Phase 1 clinical trial with TraceNETTM, a novel copper-based radio diagnostic for detecting neuroendocrine tumors (NET).
Request a sample and discover the recent breakthroughs happening in the Neuroendocrine Tumors pipeline landscape @ Neuroendocrine Tumors Pipeline Outlook
Neuroendocrine Tumors Overview
A neuroendocrine cancer, also known as a neuroendocrine tumor (NET) or neuroendocrine neoplasm, starts in the body’s neuroendocrine system’s specialized cells. These cells have characteristics of both hormone-producing endocrine cells and nerve cells. They are found in all organs and assist control many of the body’s processes. Hormones are chemical molecules that go through the bloodstream and influence the activity of other organs or cells in the body. Approximately 30% of NETs are found in the bronchial system, which transports air to the lungs. Lung NETs were previously known as carcinoid tumors. Approximately 7% of NETs can grow in the pancreas, a pear-shaped gland positioned between the stomach and the spine in the abdomen. Pancreatic NETs were previously known as islet cell tumors. A NET diagnosis necessitates a multidisciplinary team effort comprising medical oncologists, surgeons, interventional radiologists, and pathologists. Pathology, hormonal, and diagnostic and functional imaging results are used to give a comprehensive diagnostic picture. Individualized treatment regimens are developed based on tumor characteristics such as location, stage, grade, differentiation, and symptoms, as well as patient characteristics such as age and comorbidities.
Find out more about Neuroendocrine Tumors medication @ Neuroendocrine Tumors Pipeline Report
Neuroendocrine Tumors Treatment Analysis: Drug Profile
ITM-11: ITM Solucin
ITM-11, an ITM therapeutic radiopharmaceutical candidate being studied in phase III clinical trials COMPETE and COMPOSE, is made up of two parts: the medical radioisotope no-carrier-added lutetium-177 (n.c.a. 177Lu) and the targeting molecule edotreotide, a synthetic form of the peptide hormone somatostatin that targets neuroendocrine tumor-specific receptors. Edotreotide binds to these receptors and directs the medical radioisotope lutetium-177 to the sick neuroendocrine cells, where it accumulates at the tumor location. N.c.a. lutetium-177 enters tumor cells and decays, emitting medical radiation (ionizing -radiation) with a maximal radius of 1.7 mm and killing tumor tissue. Because of the highly precise localization, the healthy tissue surrounding the targeted tumor may be slightly impacted. The drug is currently under Phase III clinical trial evaluation for the treatment of Neuroendocrine Tumors.
Alphamedix: RadioMedix
AlphaMedix is an experimental radiolabeled SSTR-targeting therapeutic medication for the treatment of NETs patients. The product is an SSTR-targeting peptide complex radiolabeled with 212Pb that acts as an alpha-emitting particle generator in vivo. Because of its half-life, energy, and decay properties, the 212Pb isotope is highly ideal for SSTR treatment applications. The medication is currently in Phase II clinical trials for the treatment of Neuroendocrine Tumors.
Key Neuroendocrine Tumors Therapies and Companies
- 177Lu-edotreotide PRRT: ITM Solucin
- Axitinib: Pfizer
- AlphaMedix: Radiomedix, Inc./Orano Med LLC
- 64Cu MeCOSar Octreotate: Clarity Pharmaceuticals
- Foslinanib: TaiRx
- Belzutifan: Merck Sharp & Dohme LLC
- Actinium-225 Dotate: RayzeBio
- Pelcitoclax: Ascentage Pharma
- Debio 4126 controlled release: Debiopharm
- BI 764532: Boehringer Ingelheim
- RO7616789: Roche
Learn more about the novel and emerging Neuroendocrine Tumors pipeline therapies @ Neuroendocrine Tumors Clinical Trials
Neuroendocrine Tumors Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- By Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Scope of the Neuroendocrine Tumors Pipeline Report
- Coverage: Global
- Key Neuroendocrine Tumors Companies: Jiangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Pfizer, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others.
- Key Neuroendocrine Tumors Pipeline Therapies: 177Lu-edotreotide PRRT, Axitinib, AlphaMedix, 64Cu MeCOSar Octreotate, Foslinanib, Belzutifan, Actinium-225 Dotate, Pelcitoclax, Debio 4126 controlled release, BI 764532, RO7616789, Satoreotide trizoxetan, rSIFN-co, CAM-2029, RRx-001, Lenvatinib, PEN-221, Belzutifan, Tirapazamine, Sunitinib, NP-101, PT217, FF-10850, Lurbinectedin, 23ME-00610, BLU-667, CC-223, Paltusotine, TAK 580, PV-10, NV 103, and others.
Dive deep into rich insights for drugs used for Neuroendocrine Tumors treatment; visit @ Neuroendocrine Tumors Drugs
Table of Contents
|
1. |
Introduction |
|
2. |
Executive Summary |
|
3. |
Neuroendocrine Tumors Pipeline: Overview |
|
4. |
Analytical Perspective In-depth Commercial Assessment |
|
5. |
Neuroendocrine Tumors Pipeline Therapeutics |
|
6. |
Neuroendocrine Tumors Pipeline: Late-Stage Products (Phase III) |
|
7. |
Neuroendocrine Tumors Pipeline: Late-Stage Products (Phase III) |
|
8. |
Neuroendocrine Tumors Pipeline: Mid-Stage Products (Phase II) |
|
9. |
Neuroendocrine Tumors Pipeline: Early Stage Products (Phase I) |
|
10. |
Therapeutic Assessment |
|
11. |
Inactive Products |
|
12. |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13. |
Key Companies |
|
14. |
Key Products |
|
15. |
Unmet Needs |
|
16. |
Market Drivers and Barriers |
|
17. |
Future Perspectives and Conclusion |
|
18. |
Analyst Views |
|
19. |
Appendix |
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting